Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center
June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
GeneVentiv Therapeutics Expands Scientific Advisory Board
March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...
GeneVentiv Announces Appointment to Scientific Advisory Board
January 12, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the...
Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia
GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...
In the News
UNC-Chapel Hill gene therapy spinout raises $1.4 million
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
Bootstrapped UNC spinout lands $300K for gene therapy work
The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone - Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In March,...
Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
GeneVentiv Therapeutics Wins KickStart Commercialization Grant
Shar March 16, 2022 By Shellie Edge KickStart Venture Services – the premier life sciences startup program and accelerator from Innovate Carolina – has awarded commercialization grants to two UNC-affiliated startup companies, Elipsys, LLC, and GeneVentiv Therapeutics,...
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect
https://wraltechwire.com/2022/03/07/startup-spotlight-presenting-companies-to-pitch-at-ceds-venture-connect/
Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...
Universal hope for hemophilia
Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status
Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...
100+ companies will participate in CED’s Venture Connect – here’s who made the cut
by WRAL TechWire — January 29, 2021 RESEARCH TRIANGLE PARK – More than 100 startups and emerging entrepreneurial companies will participate in the Venture Connect 2021 summit, the Council for Entrepreneurial Development announced today. The event is set for March...